short-term treatment of all grades of erosive esophagitis;
maintenance of healing of erosive esophagitis;
long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome;
in combination with amoxicillin plus clarithromycin or amoxicillin alone (in patients intolerant or resistant to clarithromycin) for the eradication of H. pylori in patients with active or recurrent duodenal ulcers;
short-term treatment and symptomatic relief of active benign gastric ulcer (including NSAID-associated gastric ulcer in patients who continue NSAID use and for reducing risk of NSAID-associated gastric ulcer in patients with a history of NSAID-associated gastric ulcer);
treatment of heartburn and other symptoms of gastroesophageal reflux disease (GERD).
Absorption: Absorption is rapid. Tmax is approximately 1.7 h. Cmax and AUC are approximately proportional in doses from 15 to 60 mg single dose administration. Absolute bioavailability is over 80%. Cmax and AUC decrease 50% if given 30 min after food.
Distribution: Protein binding (97%) is constant over the concentration range of 0.05 to 5 mcg/mL.
Metabolism: Extensively metabolized in the liver. Metabolites are hydroxylated sulfonyl and sulfone derivatives (very little activity).
Excretion: Significant biliary excretion of the metabolites. Mean t½ is 1.9 to 2.9 h.